Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/207684
Title: | Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry |
Author: | Calafat, Margalida Torres, Paola Tosca Cuquerella, Joan Sánchez Aldehuelo, Rubén Rivero, Montserrat Iborra, Marisa González Vivo, María Vera, Isabel Castro, Luisa de Bujanda, Luis Barreiro de Acosta, Manuel González Muñoza, Carlos Calvet, Xavier Benítez, José Manuel Llorente Barrio, Mónica Surís, Gerard Cañete, Fiorella Arias García, Lara Monfort, David Castaño García, Andrés Garcia Alonso, Francisco Javier Huguet, José M. Marín Jímenez, Ignacio Lorente, Rufo Martín Cardona, Albert Ferrer, Juan Ángel Camo, Patricia Gisbert, Javier P. Pajares, Ramón Gomollón, Fernando Castro Poceiro, Jesús Morales Alvarado, Jair Llaó, Jordina Rodríguez, Andrés Rodríguez, Cristina Pérez Galindo, Pablo Navarro, Mercè Jiménez García, Nuria Carrillo Palau, Marta Blázquez Gómez, Isabel Sesé, Eva Almela, Pedro Ramírez de la Piscina, Patricia Taxonera, Carlos Rodríguez Lago, Iago Cabrinety, Lidia Vela, Milagros Mínguez, Miguel Mesonero, Francisco García, María José Aguas, Mariam Márquez, Lucía Silva Porto, Marisol Pineda, Juan R. García Etxebarría, Koldo Bertoletti, Federico Brunet, Eduard Mañosa, Míriam Domènech, Eugeni |
Keywords: | Colitis ulcerosa Teràpia intravenosa Ulcerative colitis Intravenous therapy |
Issue Date: | 5-Jan-2024 |
Publisher: | SAGE Publications |
Abstract: | Infliximab seems to be the most efficacious of the three available anti-TNF agents for ulcerative colitis (UC) but little is known when it is used as the second anti-TNF.Objectives:To compare the clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in UC patients.Design:Retrospective observational study.Methods:Patients from the ENEIDA registry treated consecutively with infliximab and a subcutaneous anti-TNF (or vice versa), naive to other biological agents, were identified and grouped according to the administration route of the first anti-TNF into IVi (intravenous initially) or SCi (subcutaneous initially).Results:Overall, 473 UC patients were included (330 IVi and 143 SCi). Clinical response at week 14 was 42.7% and 48.3% in the IVi and SCi groups (non-statistically significant), respectively. Clinical remission rates at week 52 were 32.8% and 31.4% in the IVi and SCi groups (nonsignificant differences), respectively. A propensity-matched score analysis showed a higher clinical response rate at week 14 in the SCi group and higher treatment persistence in the IVi group. Regarding long-term outcomes, dose escalation and discontinuation due to the primary failure of the first anti-TNF and more severe disease activity at the beginning of the second anti-TNF were inversely associated with clinical remission.Conclusion:The use of a second anti-TNF for UC seems to be reasonable in terms of efficacy, although it is particularly reduced in the case of the primary failure of the first anti-TNF. Whether the second anti-TNF is infliximab or subcutaneous does not seem to affect efficacy. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents. Data from the ENEIDA registryBackground: Infliximab seems to be the most efficacious of the three available anti-TNF agents for ulcerative colitis (UC), but little is known when it is used as the second anti-TNF. Objectives: To compare the clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in UC patients. Design: Retrospective observational study. Methods: Patients from the ENEIDA registry treated consecutively with infliximab and a subcutaneous anti-TNF (or vice versa), naive to other biological agents, were identified and grouped according to the administration route of the first anti-TNF into IVi (intravenous initially) or SCi (subcutaneous initially). Results: Overall, 473 UC patients were included (330 IVi, 143 SCi). Clinical response at week 14 was 42.7% and 48.3% in the IVi and SCi groups (non-statistically significant), respectively. Clinical remission rates at week 52 were 32.8% and 31.4%, in the IVi and SCi groups (nonsignificant differences), respectively. A propensity-matched score analysis showed a higher clinical response rate at week 14 in the SCi group and higher treatment persistence in the IVi group. Regarding long-term outcomes, dose escalation and discontinuation due to the primary failure of the first anti-TNF and more severe disease activity at the beginning of the second anti-TNF were inversely associated with clinical remission. Conclusion: The use of a second anti-TNF for UC seems to be reasonable in terms of efficacy, although it is particularly reduced in the case of the primary failure of the first anti-TNF. Whether the second anti-TNF is infliximab or subcutaneous does not seem to affect efficacy. |
Note: | Reproducció del document publicat a: https://doi.org/10.1177/17562848231221713 |
It is part of: | Therapeutic Advances in Gastroenterology, 2024, vol. 17 |
URI: | http://hdl.handle.net/2445/207684 |
Related resource: | https://doi.org/10.1177/17562848231221713 |
ISSN: | 1756-2848 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
calafat-et-al-2024-clinical-and-treatment-outcomes-of-a-second-subcutaneous-or-intravenous-anti-tnf-in-patients-with.pdf | 485.15 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License